Cambridge, UK, March 17, 2025: SOLASCURE Ltd (SolasCure), a biotechnology company developing a novel treatment to transform chronic wound healing, announced the initiation of a new Phase II clinical trial, CLEANVLU2. The enrollment of the trial’s first patient marks a new clinical milestone in the development of its investigational product, Aurase Wound Gel, for the treatment of chronic wounds.

Aurase Wound Gel is a hydrogel releasing Tarumase, a recombinant enzyme originally cloned from medical maggots that selectively targets fibrin, collagen, and elastin in wounds to promote healing through debridement and wound bed preparation. CLEANVLU2 adds further insight to the successful Phase IIa clinical study, CLEANVLU, which established proof-of-concept, a strong safety profile, and pain-free application. The new randomised controlled trial will explore the efficacy of Tarumase at higher concentration, in patients with venous leg ulcers.

Read the full press release at solascure.com.